Use of intralesional or subcutaneous amphotericin B associated for the treatment of feline
sporotrichosis
Feline, complex Sporothrix schenckii, refractory, recurrent, treatment
This work will happen in feline exclusive clinic of the Small Animal Hospital of Federal Rural University of Rio de Janeiro (UFRRJ in Portuguese). The goal will be to evaluate intralesional treatment with amphotericin B efficacy or subcutaneous administration associated with oral itraconazole in recurrent or resistant sporotrichosis in domestic cats. It will be chosen 20 cats, with different races, both genders and with confirmation of the sporotrichosis infection by mycological culture. These animals will be divided in two groups and submitted to different protocols of treatment. Group one is going to be the cats with a single lesion and located in one spot, with or without nasal mucosa damage. The treatment will be intralesional injection of amphotericin B with a seven days pause between the procedures, and will be made at least five sections. Group two is going to be cats with single or multiple lesions, with or without nasal mucosa damage. The treatment will be with subcutaneous administration of amphotericin B, made weekly, during five weeks, associated with daily oral itraconazole. In both groups the animals has to be refractory with single itraconazole treatment with the dose of oral 100mg/cat every 24 hours, or reinfection after clinical dismiss. The groups will receive oral itraconazole for 30 days after the last amphotericin B administration. All of the animals will be weekly evaluated to see clinical evolution trough physical and laboratorial exams. Cats will be evaluated during and after treatment whit amphotericin B, with 12 hours fasted laboratorial exams: hemogram, urea, seric creatinine, ALT, albumin, EAS, urinary GGT and protein creatinine urinary relation. Before and after the treatment all the animals will be submitted to a serical dosage of simetric dimetilarginine. The treatment efficacy will be measure by the clinical resolution that has to be reached after 30 days of the last section of amphotericin B, when itraconazole will be suspended.